---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Zanubrutinib - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/zanubrutinib
version: v1
---

# Zanubrutinib - NCI

# Zanubrutinib

Placeholder slot

(ZAN-yoo-BROO-tih-nib)

This page contains brief information about zanubrutinib (Brukinsa)
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Brukinsa

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e08fe23-d70e-424c-bc51-1222e320f902)

## Use in Cancer

Zanubrutinib
is approved to be used alone or with other drugs to treat adults with:

- **[Chronic lymphocytic leukemia or small lymphocytic lymphoma](/Common/PopUps/popDefinition.aspx?id=641290&version=Patient&language=English).**
- **[Follicular lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English)** in patients who have received at least two types of [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English) but it did not work or is no longer working. It is used with [obinutuzumab](/Common/PopUps/popDefinition.aspx?id=754339&version=Patient&language=English).¹
- **[Mantle cell lymphoma](/Common/PopUps/popDefinition.aspx?id=445048&version=Patient&language=English)** in patients who have received at least one other type of treatment.¹
- **[Marginal zone lymphoma](/Common/PopUps/popDefinition.aspx?id=543124&version=Patient&language=English)** in patients who have received at least one anti-[CD20](/Common/PopUps/popDefinition.aspx?id=721283&version=Patient&language=English)-based therapy but it did not work or is no longer working.¹
- **[Waldenström macroglobulinemia](/Common/PopUps/popDefinition.aspx?id=44854&version=Patient&language=English).**

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, a [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that zanubrutinib provides a clinical benefit in these patients.

Zanubrutinib
is also being studied in the treatment of other types of
cancer.

## More About Zanubrutinib

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/768510) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Zanubrutinib](https://medlineplus.gov/druginfo/meds/a620009.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Zanubrutinib’s Approval Improves Targeted Treatment for CLL](https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-zanubrutinib-cll-sll)

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Zanubrutinib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C141428) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
